The inhibition mechanism of a polysaccharide anticoagulant, depolymerized holothurian glycosaminoglycan (DHG), was examined by analyzing its effects on the clotting time of human plasma depleted of antithrombin 111 (ATIII), of heparin cofactor II (HCII), or of both heparin cofactors. The effect exerted by this agent on the activation of prothrombin and factor X in purified human components were also examined and all effects were compared with those of other glycosaminoglycans (GAGs). The capacity of DHG t o prolong activated partial thromboplastin time was not reduced in ATIIIdepleted, HCII-depleted, or ATIII-and HCII-depleted plasma, whereas its capacity t o prolong prothrombin time and thrombin clotting time was reduced in HCII-depleted plasma. DHG inhibited the amidolytic activity of thrombin in the presence of HCll with a second order rate constant of 1.2 x IO8 (mol/L)-' min-l. These results indicated that DHG has two different inhibitory activities, one being an HCII-LYCOSAMINOGLYCANS (GAGs) are a group of anticoagulants that are effective therapeutic agents for venous thrombosis. The mechanism responsible for their inhibitory action on coagulation has been extensively studied for unfractionated heparin (UFH), low molecular weight heparin (LMWH), and dermatan sulfate (DS); this inhibition appears to be mediated mainly by plasma protease inhibitors. It has been established that UFH inhibits thrombin, factor Xa, and other coagulation enzymes in the presence of antithrombin 111 (ATIII)'** and that LMWH inhibits factor Xa in the presence of ATIII to a greater extent than it inhibits t h r~m b i n .~-~ However, recent studies have shown that both UFH and LMWH exert their antithrombotic effects primarily through their ability to accelerate thrombin inhibition by ATIII,7"2 although UFH has an additional inhibitory effect on thrombin in the presence of heparin cofactor I1 (HCII).l3 On the other hand, DS selectively inhibits thrombin activity in the presence of HCII.I4
The inhibition mechanism of a polysaccharide anticoagulant, depolymerized holothurian glycosaminoglycan (DHG), was examined by analyzing its effects on the clotting time of human plasma depleted of antithrombin 111 (ATIII), of heparin cofactor II (HCII), or of both heparin cofactors. The effect exerted by this agent on the activation of prothrombin and factor X in purified human components were also examined and all effects were compared with those of other glycosaminoglycans (GAGs). The capacity of DHG t o prolong activated partial thromboplastin time was not reduced in ATIIIdepleted, HCII-depleted, or ATIII-and HCII-depleted plasma, whereas its capacity t o prolong prothrombin time and thrombin clotting time was reduced in HCII-depleted plasma. DHG inhibited the amidolytic activity of thrombin in the presence of HCll with a second order rate constant of 1.2 x IO8 (mol/L)-' min-l. These results indicated that DHG has two different inhibitory activities, one being an HCII-LYCOSAMINOGLYCANS (GAGs) are a group of anticoagulants that are effective therapeutic agents for venous thrombosis. The mechanism responsible for their inhibitory action on coagulation has been extensively studied for unfractionated heparin (UFH), low molecular weight heparin (LMWH), and dermatan sulfate (DS); this inhibition appears to be mediated mainly by plasma protease inhibitors. It has been established that UFH inhibits thrombin, factor Xa, and other coagulation enzymes in the presence of antithrombin 111 (ATIII)'** and that LMWH inhibits factor Xa in the presence of ATIII to a greater extent than it inhibits t h r~m b i n .~-~ However, recent studies have shown that both UFH and LMWH exert their antithrombotic effects primarily through their ability to accelerate thrombin inhibition by ATIII,7"2 although UFH has an additional inhibitory effect on thrombin in the presence of heparin cofactor I1 (HCII).l3 On the other hand, DS selectively inhibits thrombin activity in the presence of HCII. I4 In a previous study, 15 we reported a new GAG with antithrombotic and anticoagulant activities, depolymerized holothurian (holothurian means sea cucumber) glycosaminoglycan (DHG)-l, a depolymerized fragment of the GAG extracted from sea cucumber, Stichopus juponicus Selenka. We found that DHG-1 induced the prolongation of APTT in human plasma; this effect was independent of ATIII, as shown by results with ATIII-depleted plasma. However, the surface-induced generation of factor IXa was not inhibited by DHG-1. To use this depolymerized GAG as a new therapeutic agent, we developed a large-scale method of depolymerizing the holothurian GAG; we obtained a depolymerized GAG with similar properties to DHG-1, but of different molecular size from DHG-1.I6 Although the newly obtained GAG shares the same properties as DHG-l in terms of anticoagulant activity, we named it DHG to distinguish it from DHG-1. In the present study, we examined the in vitro anticoagulant activity of DHG in two experimental systems. dependent thrombin inhibition and the other an ATIII-and HCII-independent inhibition of the coagulation cascade. The heparin cofactors-independent inhibitory activity of DHG was investigated in the activation of prothrombin by factor Xa and in the activation of factor X by tissue factor-factor Vlla complex or by factor IXa. DHG significantly inhibited the activation of factor X by factor IXa in the presence of factor Vllla, but not in the absence of factor Vllla. The interaction between DHG and factors IXa, Vllla, and X was investigated with a DHG-cellulofine column, on which DHG had strong affinity for factors IXa and Vllla. These findings show that the heparin cofactors-independent inhibition exhibited by DHG was caused by inhibition of the interaction of factor X with the intrinsic factor Xase complex, probably by binding to the factor IXa-factor Vllla complex. 0 1995 by The American Society of Hematology.
First, we prepared plasma that was depleted of either ATIII or HCII and plasma depleted of both heparin cofactors and compared the anticoagulant activity of DHG in these plasmas with the anticoagulant activity of UFH, LMWH, and DS. We then examined the inhibitory activity of DHG on thrombin and on the activation of prothrombin and factor X using purified human components. Our findings indicate that DHG is an anticoagulant with two different inhibitory activities, one being the HCII-dependent inhibition of thrombin and the other the ATIII-and HCII-independent inhibition of the activation of factor X by the factor IXa-factor VIIIa complex. from Peptide Institute (Osaka, Japan), respectively. Bovine brain cephalin was purchased from Sigma Diagnostics (St Louis, MO) and dissolved according to the manufacturer's instruction. Bovine serum albumin (BSA), phosphatidylserine (PS), and phosphatidylcholine (PC) were purchased from Sigma Chemical Co. DHG (average molecular weight 10,000 to 15,000) was prepared by depolymerization of extracts of Sfichopus japonicus Selenka." Its structure was determined to be a fucose-branched chondroitin 4f-sulfate by means of chemical degradation and 2D-NMR spectroscopy" (Fig l) .
Pooled human plasma was obtained from IO healthy donors with informed consent and stored at -70°C until use. Human ATIII was purchased from Cosmo Bio CO (Tokyo, Japan). Human HCII was purified as described by Tran et al." Its homogeneity was confirmed on sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Human thrombin and human factor Xa were purchased from Diagnostica Stago (Asnieres, France) and from Enzyme Research Laboratories (South Bend, IN), respectively. Human factor X and factor VIIa were kindly supplied by The Chemo-Sero-Therapeutic Foundation (Kumamoto, Japan). Human factor IX was purified as reported previously'* and activated to factor IXa by factor XIa. Factor Xla was prepared by the activation of factor XI with factor XIIa, which were products of Enzyme Research Labs, Inc. Human factor VIIIa was prepared by the activation of recombinant factor VI11 (9.1 nmol/L; Kogenate; Bayer Yakuhin, Ltd, Osaka, Japan) with human thrombin (1.6 nmol/L; Sigma Chemical CO) for 1 minute at 37°C before use. Human recombinant tissue factor (TF) was purchased from Corvas (San Diego, CA). Human prothrombin was purified from pooled plasma, as described elsewhere." Human factor Va was prepared by the activation of factor V (150 nmol/L; Diagnostics Stago) with human thrombin (1.6 nmoVL) for 3 minutes at 37°C before use. A phospholipid micelle consisting of 25% phosphatidylcholine and 75% phosphatidylserine (Sigma Chemical CO) was prepared by sonication of a phospholipid suspension in 20 mmol/L Tris-HCI, pH 8.0, containing 0.15 molL NaCI.
Profein concentrafion. The concentrations of human coagulation factors IXa, X, Xa, VIII(VIIIa), VIla, V(Va), prothrombin, thrombin, and HCII were calculated from absorbance at 280 nm using extinction coefficient values or specific activities and molecular weights.2szx
Preparation of ATIII-depleted or HCII-depleted plasmas. Antisera against ATIII and HCII were obtained from rabbits immunized with each protein. The IgG were isolated using a column conjugated with ATIII or HCII. They were coupled with CNBr-activated Sepharose 4B (Pharmacia Biotechnology, Uppsala, Sweden; 25 mg/g of dried gel). Pooled human plasma (20 mL) was passed through an affinity column (1.5 X 8.5 cm) equilibrated with 20 mmol/L Tris-HCI, pH 7.4, containing 0.15 molL NaCI. In the breakthrough fraction from an anti-AT111 IgG column, ATIII activity measured according to Odegard et al" was not detected. Human plasma or the breakthrough fraction from the anti-ATIII IgG column was applied to an anti-HCII IgG column. HCII activity in the breakthrough fraction from the column, measured using a Stachrom HClI kit (Diagnostics Stago), was less than 2%. The total protein concentration in each of the depleted plasmas was unchanged.
Cougulufion ussu?;. Activated partial thromboplastin time (APTT) and thrombin clotting time (TCT) were determined by using a commercially available APTT reagent (Platelin Excel LS: Organon Teknika CO, Durham, NC) and human thrombin (3,000 U/mg protein; Sigma Chemical CO). Prothrombin time (PT) was determined by a standard method using tissue thromboplastin extracted from rabbit brain (Simplastin; Organon Teknika CO). The PT reagent was diluted in 0.025 mol/L CaCI, at 1:30, so that the PT of normal plasma was 30.4 seconds. The effects of the GAGs on A m , TCT. and PT were tested by the addition of 10 p L of sample to 100 pL of plasma. Prothrombin activation in contact-activated normal plasma and factor IXa generation in glass surface-activated factor VIII-deficient plasma (George King Bio-Medical, Inc. Overland Park, KS) were measured as described previously."
Antifhrombin and anti-factorxu chromogenic assay. Antithrombin and anti-factor Xa activities in the presence of ATllI were measured with S-2238 and S-2222, respectively, as described pre- Kinetic analysis of anfifhrombin activity. Thrombin (33 pmol/ L) and HCII (6.5 nmolL) were incubated with various amounts of GAGS in 200 pL of TBS-BSA (20 mmol/L Tris-HCI buffer, pH 8.0, containing 150 mmol/L NaCI, 0.1 mg BSA/mL, and 0.05% NaN2). At various time intervals, portions were removed and residual thrombin activity was determined by the addition of Boc-Val-Pro-Arg-MCA (final concentration, 100 pmol/L). The AMC liberated was measured as described previously'" using a flurescence spectrophotometer (model F-4500;
Hitachi Ltd, Tokyo, Japan). The second order rate constant was determined according to the equation, k? = -In(E,/EO)/([Il)]t), where t is the reaction time; E, and E,, are remaining thrombin activity at time t and initial thrombin activity, respectively; and [ll,] is the initial inhibitor (HCII) concentration.'' Activation of facrorX by fucfor IXu. Ten microliters of 9. I moll L factor VIIIa was mixed with 965 p L of TBS-BSA containing 0.18 nmol/L factor IXa, Cephalin (55 pL), 5 mmol/L CaCl, and various amounts of GAGs. After 30 seconds, factor X activation was initiated by adding 2.5 pL of 2.8 pmol/L factor X to the mixture (final concentrations: factor IXa, 180 pmol/L: factor VIIIa, 9 1 pmol/L; factor X, 70 nmol/L). After incubation at 37°C for 1 minute, the factor Xa generated was measured by the addition of 1 mL of a mixture of ZPyr-Gly-Arg-MCA (final concentration, 1 OO pmol/L) and EDTA (final concentration, 10 mmol/L). When factor VIIIa was excluded, the reaction mixture containing 34 nmol/L factor IXa and 270 m o l / L factor X was incubated for 15 minutes. The AMC liberated was measured using a fluorescence spectrophotometer (model F-4500; Hitachi Ltd) or a centrifugal autoanalyzer (Cobas Bio) equipped with a fluorescence unit.
Activation of jucfor X by factor Vlla-tissue factor. Factor X activation was initiated by mixing 240 p L of TBS-BSA containing recombinant tissue factor (1.3 ng), a mixture of 25% PC and 75% PS, 66 pmol/L factor VIIa, and 5 mmol/L CaCI,, with 20 pL of a mixture of 360 nmolL factor X and various amounts of GAGs (final Concentrations of GAGs are expressed as micrograms per milliliter of plasma. A mixture of 100 pL of plasma and 10 pL of various concentrations of GAGs was incubated with 100 pL of A P T reagent at 37°C for 5 minutes; 100 pL of 25 mmoVL CaCI, was then added. A P T for normal, ATIII-depleted, HCII-depleted, and both heparin cofactorsdepleted plasma was 33.1, 33.5, 34.0, and 36.3 seconds, respectively.
concentrations: factor VIla, 61 pmol/L; factor X, 27 nmoVL). After incubation at 37°C for 10 minutes, the factor Xa generated was measured as described above.
Activation of prothrombin by factor Xu. Ten microliters of 150 nmoliL factor Va was mixed with 970 pL of TBS-BSA containing 2.2 pmoVL factor Xa, Cephalin (55 pL), 5 mmom CaCI2, and various amounts of GAGs. After 30 seconds, prothrombin activation was initiated by adding 20 pL of 2.4 mmol/L prothrombin to the mixture (final concentrations: factor Xa, 2.2 pmoVL; factor Va, 1.5 nmo1iL; prothrombin, 48 nmoVL). After incubation at 37°C for 30 seconds, the thrombin generated was measured by the addition of 1 mL of a mixture of Boc-Val-Pro-Arg-MCA (final concentration, 100 pmollL) and EDTA (final concentration, 10 mmoVL). as described above. When factor Va was excluded, reaction mixture containing 1.5 nrnolk factor Xa and 120 nmol/L prothrombin was incubated for 5 minutes.
Analysis of ajinities of blood coagulation factors to DHG-cellulofine column. Factor IXa (410 pg), factor VIIIa (5 pg), or factor X (820 pg) was applied to a DHG-cellulofine (Chisso Corp. Chiba, Japan) column (0.8 X 7.5 cm) in 20 mmoVL Tris-HCI, pH 8.0, containing 150 mmoUL NaC1, 5 mmoVL CaCI,, 0.01% Tween 80, and 0.05% NaN3 at room temperature. The columns were washed free of unbound proteins with the same buffer. Elution was accomplished with a 60 mL linear NaCl gradient (0.15 to l mom). Onemilliliter fractions were collected at a flow rate of 1 mL/min at 4°C. In the case of factors IXa and X, the absorbance at 280 nm of each fraction was measured. The factor VIIIa activity of each fraction was measured by determining the APTT of factor VIII-deficient plasma, using human plasma as a standard. In a control experiment, an acetylated amino cellulofine (Chisso Corp) column was used instead of a DHG column. depleted, and both heparin cofactors-depleted plasma, whereas the capacity of DHG to prolong PT was reduced in HCII-depleted and in ATIII-and HCII-depleted plasma, but was not significantly reduced in ATIII-depleted plasma. These results indicate that the prolongation of APTT by DHG is independent of ATIII and HCII, whereas the prolongation of PT depends on HCII. The inhibitory potency of UFH and LMWH on APTT and PT was markedly reduced in ATIII-depleted plasma, but not in HCII-depleted plasma, whereas that of DS was reduced in HCII-depleted plasma. These results confirm previous findings that the prolongation of clotting time induced by UFH and LMWH depends on ATIII, whereas that induced by DS depends on HCII." TCT in normal plasma was prolonged most potently by UFH and less potently by LMWH, DHG, and DS in that order (data not shown). TCT prolongation by DHG and DS was markedly reduced in HCII-depleted plasma, whereas the prolongation of TCT by UFH and LMWH was reduced in ATIII-depleted plasma. In the plasma depleted of both heparin cofactors, TCT was not significantly prolonged by each 
RESULTS
Effects of DHG and other GAGs on clotting time of normal, ATIII-depleted, HCII-depleted, and both heparin cofactors-depleted plasma. The capacity of GAGs to prolong APTT and PT was expressed as the concentrations required to double APTT and PT (doubling APTT and doubling PT; Tables 1 and 2 ). In normal plasma, the doubling AFTT of DHG was smaller than the doubling PT. These values were smaller than those for the previous DHG preparation, DHGl. I5 The doubling APTT of DHG in normal plasma was approximately the same as those in ATIII-depleted, HCII- Values indicate TCT (seconds) of plasma in the presence of GAGs at the concentrations required to double the APlT of normal plasma (shown in parentheses) (see Table 1 ). A mixture of 100 pL of plasma, 100 pL of 20 mmol/L imidazole buffer (pH 7.4), and 10 pL of each GAG was incubated at 37°C for 1 minutes; 100 pL of human thrombin (2.5 NIH U/mL) was then added.
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For personal use only. on November 11, 2017. by guest www.bloodjournal.org From of the GAGs. These results indicate that DHG and DS prolonged TCT HCII dependently and that UFH and LMWH did mainly ATIII dependently. Table 3 shows the TCT of normal, ATIII-depleted, HCII-depleted, and both heparin cofactors-depleted plasma in the presence of GAGs at the concentrations of which they doubled APTT. In normal plasma, DHG at doubling APTT caused slight prolongation of TCT, whereas UFH, LMWH, and DS markedly prolonged TCT at doubling AFTT. TCT prolonged by DHG and DS at doubling APTT was reduced in HCII-depleted plasma, whereas TCT prolonged by UFH and LMWH at doubling APTT was reduced in ATIII-depleted plasma. These results suggest that the major inhibitory activity of DHG is the prolongation of APTT, which is independent of ATIII and HCII, although DHG also had HCII-dependent inhibitory activity on thrombin.
Factor IXa generated by glass surface activation of factor VIII-deficient plasma was measured using factor IX-deficient plasma as described in Subjects, Materials, and Methods. The clotting time of factor IX-deficient plasma was reduced to 71.9 from 557.8 seconds by glass-surface activation for 24 minutes. In the presence of DHG (3.8 pg/mL), it was reduced to 76.8 from 461.7 seconds. These results suggest that factor IXa generation was not inhibited by DHG at doubling APTT. Figure 2 shows the retardation of prothrombin consumption in contact-activated plasma by GAGs at the concentration of doubling APTT. In normal plasma, all the polysaccharide anticoagulants retarded prothrombin comsumption with approximately the same potency (Fig 2A) . In ATIIIand HCII-depleted plasma, in contrast, only DHG retarded prothrombin comsumption (Fig 2B) . The inhibitory effect of UFH and LMWH disappeared in ATIII-depleted plasma, whereas that of DS disappeared in HCII-depleted plasma (data not shown). These findings indicate that the retardation of prothrombin consumption by DHG in contact-activated plasma was not dependent on ATIII and HCII.
Effects of DHG and other GAGs on the amidolytic activity of thrombin and factor Xa. None of GAGs tested had any effect on the amidolytic activities of thrombin and factor Xa, at final concentrations of up to 100 pg/mL, in the absence of ATIII or HCII. In the presence of ATIII, DHG showed weak inhibition of thrombin (ICso = 35.9 pg/mL), but no significant inhibition of factor Xa (ICso > 100 pg/mL). HOWever, DHG strongly inhibited thrombin in the presence of HCII (IC5o = 0.8 pg/mL). Figure 3A shows the effects of DHG and other GAGs on thrombin in the presence of HCII.
At their optimum concentrations, second order rate constants for the inhibition of thrombin were calculated from the data as shown in Fig 3B. The value for DHG was calculated to be 1.2 X IO8 (mol/L)"min I. The values for DS and UFH, 2.6 X 10' (mol/L"min" for DS and 1.4 X IO* (moV L)"min-l for UFH, were slightly lower than those reported previousIy.14. 33 Effects of DHG and other GAGs on the activation offactor X by factor IXa or.factor VIIa and of prothrombin by factor Xu. As described in the previous section, DHG prolonged APTT in an ATIII-and HCII-independent manner. The inhibition of prothrombin activation in contact-activated plasma was also independent of ATIII and HCII. DHG did not inhibit the generation of factor IXa in contact-activated plasma.
To clarify the mechanism of DHG inhibition in the coagulation reactions, we examined the effect of DHG, in comparison with the effects of the other GAGs, on the activation of prothrombin and factor X, using purified coagulation factors. We first examined the effects of GAGs on the activation of factor X by factor VIIa or factor IXa, measuring the amidolytic activity of factor Xa. The amidolytic activity of the factor VIIa-tissue factor complex and the activation of factor X by the factor VIIa-tissue factor complex in the presence of phospholipid and calcium ion were not inhibited by DHG, UFH, and LMWH (data not shown). On the other hand, all three GAGs inhibited the activation of factor X by factor IXa in the presence of factor VIIIa, phospholipid, and calcium ion, and this occurred in a dose-dependent manner (Fig 4A) . DHG had the strongest inhibitory activity. The effect of DHG was similar to that when DHG was added 3 &mL, they weakly accelerated thrombin formation (Fig   5B) .
AfJiity of factors IXa, VIlIa, and X to DHG-cellulojne. Factors IXa, VIIIa, and X were applied to the DHG-cellulofine column to examine the interaction between DHG and these coagulation proteins. The proteins did not bind to the control column (acetylated amino-cellulofine) under condition of the physiologic salt concentration. Factors IXa and VIIIa bound to DHG-cellulofine under this condition and were eluted at 0.55 and 0.31 m o m NaCl, respectively (Fig  6) . Although factor X did not bind to DHG-cehlofine, it v 0 .
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together with factor X. In contrast, factor X activation by factor IXa was not inhibited in the absence of factor VIIIa (Fig 4B) . Surprisingly, the formation of factor Xa in this reaction was accelerated by DHG at concentrations of 0.3
We then examined the effects of GAGs on the activation of prothrombin by factor Xa, measuring the amidolytic activity of thrombin. At concentrations exceeding 10 pg/mL, DHG, UFH, and LMWH had inhibitory effects on the activation of prothrombin by factor Xa in the presence of factor Va, phospholipid, and calcium ion (Fig 5A) . In the absence of factor Va, the GAGs, at up to 3 pg/mL, did not inhibit the activation of prothrombin. At concentrations exceeding to 300 &d. Effects of DHG and other GAGs on factor X activation by factor IXa in the presence (A) and absence (B) of factor VIIIa. (A) A mixture containing factors IXa, Vllla, X, phospholipid, calcium, and various amounts of GAGs was prepared as described under Subjects, Materials, and Methods. After 1 minute of incubation at 37°C. the factor Xa generated was measured using 2-Pyr-Gly-ArgMCA as a substrate. The activity of factor Xa generated in the absence of the GAGs was taken t o be 100%. GAG concentration (pg/ml)
Effects of DHG and other GAGs on prothrombin activation by factor Xa in the presence (A) and absence (B) of factor Va. (A) A mixture containing factors Xa and Va, prothrombin, phospholipid, calcium, and various amounts of GAGs was prepared as described under Subjects, Materials, and Methods. After 30 seconds of incubation at 37°C. the thrombin generated was measured using Boc-ValPro-Arg-MCA as a substrate. The activity of thrombin generated in the absence of GAGs was taken t o be 100%. (B) A mixture containing factor Xa, prothrombin, phospholipid, calcium, and various amounts of GAGs was prepared as described under Subjects, Materials, and Methods. Thrombin activity was measured after 5 minutes of incuba-
had slight affinity to DHG, evidenced by the finding that the peak of the passed-through fraction was broader than that of the control column. These findings indicate that DHG has a strong affinity to factors IXa and VIIIa. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From other the heparin cofactors-independent inhibition of factor X activation by the factor IXa-factor VIIIa complex.
The HCII-dependent anticoagulant activity of DHG on thrombin was shown by the following findings: (1) the prolongation of PT and TCT in normal plasma was reduced in HCII-depleted plasma and (2) the amidolytic activity of thrombin was inhibited only in the presence of HCII. However, the prolongation of APTT by DHG in normal plasma was not reduced in heparin cofactors-depleted plasma. Because the retardation of prothrombin consumption by DHG in contact-activated plasma was not dependent on ATIII and HCII and factor IXa generation in plasma induced by the glass surface was not influenced by DHG, it appeared that the heparin cofactors-independent prolongation of APTT by DHG was due to the effects exerted by DHG on the activation of prothrombin or factor X. The second order rate constant for the inhibition of thrombin activity by DHG in the presence of HCII was comparable with those for the inhibition of thrombin by DS and UFH. Although it is not known which is the major anticoagulant activity of DHG, the HCIIdependent or the two heparin cofactors-independent activity, we suggest that the major anticoagulant activity of DHG may be the heparin cofactors-independent inhibition, this being indicated by our finding that the activity of DHG in the heparin cofactors-dependent prolongations of PT and TCT was weaker than that in the heparin cofactors-independent prolongation of APTT.
To clarify the mechanism responsible for the heparin cofactors-independent anticoagulant activity of DHG, we examined the inhibitory effects of DHG on the activation of factor X and prothrombin using purified human coagulation factors. DHG had a slight inhibitory effect on the activation of prothrombin by the factor Xa-factor Va complex, whereas it had a strong inhibitory effect on the activation of factor X by the factor IXa-factor VIIIa complex. The effect of DHG on the activation of factor X was almost the same when DHG was added after the formation of the intrinsic factor Xase complex. However, DHG did not inhibit the activation of factor X by factor IXa in the absence of factor VIIIa. These findings suggested that DHG inhibited the activation of factor X through its interaction with the factor IXa-factor VIIIa complex. We then examined the interaction between DHG and the coagulation proteins, factors IXa, VIIIa, and X, using a DHG-cellulofine column. DHG had strong affinity for factors IXa and VIIIa and slight affinity for factor X. Because DHG showed a strong inhibitory effect of intrinsic factor Xase complex when DHG was added after the formation of the factor IXa-factor VIIIa complex, it is unlikely that DHG interfered with the interaction between factor IXa and factor VIIIa. We therefore presumed that DHG interfered with the interaction between intrinsic factor Xase and factor X by binding to the factor IXa-factor VIIIa complex.
Thus, the anticoagulant effects of DHG were clearly distinguished from those of UFH, LMWH, and DS, which are mediated by ATIII and HCII. In in vivo experiments in rats with thrombin-induced venous thrombus formation (data not shown; Kitazato et al, manuscript submitted), UFH and LMWH significantly prolonged the bleeding time, whereas DHG had no effect on the bleeding time in the tail transection of rats at the minimum dose of each GAG that was effective in the thrombin-induced venous thrombus formation. Thus, it appears that the heparin cofactors-independent inhibition of the intrinsic factor Xase complex may be important in the mechanism whereby the antithrombotic and haemorrhagic properties of DHG are dissociated. Further studies, for example on the effect of DHG in heparin cofactors-depleted animals, will be required to examine the contribution of this heparin cofactors-independent effect to the in vivo antithrombotic effect of DHG.
The anticoagulant effect of DHG is very similar to that of pentosan polysulfate (PPS), which inhibits thrombin HCIIdependently and prolongs APTT ATIII and HCII independentl~.~' Wagenvoord et a134 have reported that PPS inhibits factor VIIIa formation (activation of factor VI11 by thrombin) and that it inhibits the function of factor VIIIa by the formation of a factor VIIIa-PPS complex. Recently, heparin has been reported to inhibit the thrombin-catalyzed activation of factor VI11 and also the activation of factor X by the intrinsic factor Xase in the absence of ATIII and HCII.'s In light of these findings, it is clear that further investigation of the effects of DHG on the components of intrinsic factor Xase is required to elucidate the heparin cofactors-independent anticoagulant effects of DHG.
